Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (291-300 of 390) with videos related to

Pageof 39
Sort By:
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyPakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.
BMJ Neurology Open|July 30, 2025
Relationship between brain atrophy and disability in a multi-site multiple sclerosis registryAi-Lan Nguyen, Dana Horakova, Eva H Havrdova, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Multiple Sclerosis and Related Disorders|November 13, 2024
Utility of icobrain for brain volumetry in multiple sclerosis clinical practiceAi-Lan Nguyen, Maria Pia Sormani, Dana Horakova, et al.
Pageof 39

Showing results (291-300 of 390) with videos related to

Sort By:
Pageof 39
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyPakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.
BMJ Neurology Open|July 30, 2025
Relationship between brain atrophy and disability in a multi-site multiple sclerosis registryAi-Lan Nguyen, Dana Horakova, Eva H Havrdova, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Multiple Sclerosis and Related Disorders|November 13, 2024
Utility of icobrain for brain volumetry in multiple sclerosis clinical practiceAi-Lan Nguyen, Maria Pia Sormani, Dana Horakova, et al.
Pageof 39